Component
Inflammatory lesions of papulopustular rosacea
Facial inflammatory lesion burden in moderate-to-severe disease.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Topical ivermectin 1% cream was an effective treatment for moderate-to-severe papulopustular rosacea and was more effective than topical metronidazole at twelve weeks, with a number needed to treat of 10.5.
Experimental context and source evidence
- duration
- 12 weeks, with extension to 36 weeks for relapse
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- experimental_model
- Humans with moderate-to-severe papulopustular rosacea
- exposure
- Topical ivermectin 1% cream
- limitations
- Relapse after discontinuation was common in both arms, 62.7% with ivermectin and 68.4% with metronidazole by week 36, and ivermectin has only been tested in moderate-to-severe disease.
- organism
- Humans with moderate-to-severe papulopustular rosacea
- plain_language
- Topical ivermectin 1% cream was an effective treatment for moderate-to-severe papulopustular rosacea and was more effective than topical metronidazole at twelve weeks, with a number needed to treat of 10.5.
- primary_references
- Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline Recommendations. (2018). https://pubmed.ncbi.nlm.nih.gov/29943217/ DOI: 10.1007/s13555-018-0249-y
- route
- Topical
- tissue
- Inflammatory facial lesions, with acaricidal activity against Demodex mites
Ivermectin: mechanism of action across parasite, host barrier and mammalian targets (2026-09-22) · lines 233–242
Original AI-assisted curation of sixteen primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Study-specific citations, concentrations, negative findings and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft
## ivermectin-rosacea-lesions Topical ivermectin 1% cream was an effective treatment for moderate-to-severe papulopustular rosacea and was more effective than topical metronidazole at twelve weeks, with a number needed to treat of 10.5. Model/species: Humans with moderate-to-severe papulopustular rosacea Tissue/system: Inflammatory facial lesions, with acaricidal activity against Demodex mites Exposure: Topical ivermectin 1% cream Route: Topical Duration: 12 weeks, with extension to 36 weeks for relapse Limits: Relapse after discontinuation was common in both arms, 62.7% with ivermectin and 68.4% with metronidazole by week 36, and ivermectin has only been tested in moderate-to-severe disease. Primary reference: Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline Recommendations. (2018). https://pubmed.ncbi.nlm.nih.gov/29943217/ DOI: 10.1007/s13555-018-0249-y Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.